| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10963093 | Vaccine | 2016 | 5 Pages |
Abstract
All immune-compromised patients mounted an adequate response with protective levels of virus neutralizing antibodies to the 17-D YF vaccine. No adverse effects were reported. Compared to the plaque reduction neutralization test, the sensitivity of the Immune Fluorescence Assay test was low. Further research is needed to ascertain that 17D vaccination in immune-compromised patients is safe.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Rosanne W. Wieten, Emile F.F. Jonker, Daan K.J. Pieren, Caspar J. Hodiamont, Pieter P.A.M. van Thiel, Eric C.M. van Gorp, Adriëtte W. de Visser, Martin P. Grobusch, Leo G. Visser, Abraham Goorhuis,